蛋白质组学揭示了阿尔茨海默病的三种分子亚型,具有明显的进展模式
Xiao-He Hou1,2,3,4, Wei Zhang2,3,4, Kairan Kang2,3,4
1Department of Neurology, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 6, 2026
概括
研究人员使用CSF蛋白质组学识别了三个不同的阿尔茨海默病 (AD) 亚型. 这些亚型表现出不同的分子路径,临床特征和进展率,为精准医学铺平了道路.
科学领域:
- 神经科学是一个神经科学.
- 蛋白质组学是指蛋白质组学.
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 呈现出显著的分子异质性.
- 识别不同的生物亚型对于改善AD诊断和治疗策略至关重要.
研究的目的:
- 定义阿尔茨海默病的生物亚型.
- 将这些亚型与特定的分子途径和临床进展联系起来.
主要方法:
- 分析了来自550名阿尔茨海默氏病神经成像倡议参与者的脑脊液 (CSF) 蛋白质组和纵向数据.
- 机器学习被用来识别AD亚型,然后在三个独立的队列中验证.
- 分析了6361种蛋白质,以表征已识别的亚型.
主要成果:
- 鉴定出了三种不同的阿尔茨海默病亚型.
- 亚型1:富含RNA代谢,呈现最轻微的缩和最慢的认知衰退.
- 亚型2:以轴突发生路径为特征,具有高的CSF tau,中度缩和中间衰退.
- 亚型3:与代谢过程相关,表现出最严重的缩和最快的进展.
- 这些亚型模式在验证队列中被一致复制.
结论:
- 生物学上不同的阿尔茨海默病亚型,与不同的分子路径和临床轨迹相关,已经得到了强有力的证明.
- 阿尔茨海默病的这种精细分层支持精确诊断和有针对性的治疗干预措施的发展.
相关概念视频
Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K
Proteomics
7.5K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.5K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
20
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
Alzheimer Disease ll: Pathophysiology
32
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32


